Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Pfizer stock price, quote, forecast and news

PFE
US7170811035
852009

Price

29.50
Today +/-
+0
Today %
+0 %
P

Pfizer Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Pfizer, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pfizer from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pfizer’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pfizer. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pfizer’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pfizer’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pfizer’s growth potential.

Pfizer Revenue, EBIT and net profit per share

DatePfizer RevenuePfizer EBITPfizer Net Income
2029e62.09 B undefined0 undefined15.85 B undefined
2028e62.95 B undefined20.35 B undefined16.31 B undefined
2027e65 B undefined22.06 B undefined17.37 B undefined
2026e63.9 B undefined20.91 B undefined16.59 B undefined
2025e63.4 B undefined19.89 B undefined15.62 B undefined
2024e61.19 B undefined17.65 B undefined13.44 B undefined
202358.5 B undefined13.1 B undefined2.12 B undefined
2022100.33 B undefined40.16 B undefined31.37 B undefined
202181.29 B undefined27.54 B undefined21.98 B undefined
202041.91 B undefined11.72 B undefined9.62 B undefined
201941.17 B undefined9.42 B undefined16.27 B undefined
201840.83 B undefined8.74 B undefined11.15 B undefined
201752.55 B undefined15.58 B undefined21.31 B undefined
201652.82 B undefined15.06 B undefined7.21 B undefined
201548.85 B undefined13.63 B undefined6.96 B undefined
201449.61 B undefined14.66 B undefined9.13 B undefined
201351.58 B undefined17.02 B undefined22 B undefined
201254.66 B undefined17.32 B undefined14.57 B undefined
201161.04 B undefined18.76 B undefined10.01 B undefined
201065.17 B undefined17.54 B undefined8.26 B undefined
200949.27 B undefined15.89 B undefined8.63 B undefined
200848.3 B undefined16.52 B undefined8.1 B undefined
200748.42 B undefined10.86 B undefined8.14 B undefined
200648.37 B undefined15.01 B undefined19.33 B undefined
200547.41 B undefined14.53 B undefined8.08 B undefined
200448.99 B undefined16.4 B undefined11.35 B undefined

Pfizer Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
3.773.884.034.484.925.395.6711.0912.0112.8313.2714.3917.0618.5419.1323.2327.1726.0529.0232.2944.7448.9947.4148.3748.4248.349.2765.1761.0454.6651.5849.6148.8552.8252.5540.8341.1741.9181.29100.3358.561.1963.463.96562.9562.09
-2.953.8411.209.929.455.3395.578.266.813.488.4518.548.643.1721.4716.94-4.1311.4411.2738.539.50-3.232.040.10-0.252.0132.26-6.34-10.45-5.62-3.84-1.528.13-0.53-22.310.851.7993.9723.43-41.704.613.610.781.72-3.15-1.36
58.8860.5861.5961.5761.4462.4963.6365.9768.1370.0772.2173.0773.0975.6077.7378.8879.4785.5886.8387.5778.5786.9584.7484.2176.7984.7582.9978.1080.8382.0381.6480.8080.4077.4379.3778.2780.4679.5462.2566.0269.59------
2.222.352.482.763.023.373.617.328.188.999.5810.5212.4714.0114.8718.3221.5922.2925.228.2835.1542.640.1740.7337.1840.9340.8950.949.3444.8442.1140.0839.2840.941.7131.9533.1333.3350.666.2340.71000000
0.720.810.850.920.9510.841.721.952.182.392.743.453.983.974.416.918.5510.5312.2910.6316.414.5315.0110.8616.5215.8917.5418.7617.3217.0214.6613.6315.0615.588.749.4211.7227.5440.1613.117.6519.8920.9122.0620.350
19.0720.9221.1420.5119.3118.6414.7715.5316.2016.9618.0119.0620.2121.4720.7518.9725.4532.8236.2838.0423.7633.4830.6431.0422.4334.2032.2526.9230.7431.6832.9929.5527.9128.5129.6621.4022.8727.9633.8740.0322.3928.8431.3832.7333.9432.33-
0.460.520.590.670.70.80.691.290.761.450.991.992.312.722.884.634.953.737.799.133.9111.358.0819.338.148.18.638.2610.0114.57229.136.967.2121.3111.1516.279.6221.9831.372.1213.4415.6216.5917.3716.3115.85
-13.8212.9113.484.5114.53-13.9488.32-41.3291.81-31.96101.6216.1617.336.0860.876.89-24.76109.0217.18-57.20190.66-28.84139.29-57.89-0.486.57-4.3821.2245.5851.02-58.48-23.813.66195.36-47.6645.91-40.90128.5742.74-93.25534.2616.246.204.72-6.15-2.83
-----------------------------------------------
-----------------------------------------------
4.074.084.14.114.14.074.086.266.296.266.075.956.016.116.36.366.326.376.366.247.297.617.417.276.946.757.058.077.877.516.96.426.266.166.065.985.685.635.715.735.71000000
-----------------------------------------------
Details

Keystats

Revenue and Growth

The Pfizer Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pfizer is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Pfizer provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pfizer's financial health and stability.

Assets

Pfizer's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pfizer must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pfizer after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pfizer's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (B)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.690.790.681.290.761.460.991.992.312.552.943.234.973.737.799.133.9111.368.0919.348.198.138.648.2910.0514.622.079.176.997.2521.3611.1916.39.6522.0331.412.16
0.170.20.210.350.380.420.430.470.580.590.710.80.910.880.971.034.035.095.585.295.25.094.768.49.037.666.415.545.165.766.276.386.014.785.195.066.29
0000.03-0.120.01-0.470.080.080.150.02-0.160.21-0.210.19-0.29-0.1-1.58-1.38-1.53-2.79-1.33-9.582.110.240.791.730.32-0.02-0.7-2.41-2.210.61-1.47-4.29-3.76-3.44
0.460-0.22-0.15-0.3-0.54-0.46-0.5-0.44-0.06-0.520.95-0.911.850.350.31-1.28-0.86-0.582.6-0.84.8612.52-10.362.53-2.37-3.381.630.740.11.34-0.93-4.03-0.2812.8-4.46-2.17
-0.03-0.11-0.01-0.120.870.111.240.090.09-0.250.120.360.29-0.14-0.13-05.182.333.03-8.113.561.880.63.43-1.19-3.45-8.621.022.494.48-8.912.31-5.622.47-1.971.896.39
0.070.090.12000000000.260.380.460.290.260.350.50.650.720.640.780.942.162.091.871.731.551.31.451.521.311.591.641.471.442.22
0.220.270.24000000001.361.571.040.961.482.913.394.713.445.622.252.311.782.932.412.872.12.382.522.493.663.663.157.437.873.15
1.290.870.661.391.581.451.732.132.622.993.285.185.476.19.1710.1811.7316.3414.7317.5913.3518.2416.5911.4520.2416.7517.6817.0814.6916.1916.815.8312.5914.432.5829.278.7
-258-344-456-788-920-1,008-981-1,078-1,083-1,079-1,391-2,181-2,746-2,247-2,332-2,286-3,417-2,928-2,537-2,203-1,880-1,701-1,205-1,513-1,882-1,419-1,465-1,583-1,496-1,999-2,217-2,196-2,594-2,791-2,711-3,236-3,907
-1.11-0.96-0.63-0.56-0.430.06-0.96-1.54-2.71-1.96-1.62-0.77-3.91-3.64-7.14-4.344.85-9.42-5.075.10.8-12.84-31.27-0.491.846.15-10.54-5.65-2.98-7.79-4.744.53-3.95-4.27-22.55-15.78-32.28
-0.85-0.61-0.170.230.491.060.02-0.46-1.63-0.89-0.231.41-1.16-1.39-4.8-2.058.27-6.49-2.547.32.68-11.13-30.071.023.737.57-9.08-4.07-1.48-5.79-2.526.72-1.35-1.48-19.84-12.55-28.37
0000000000000000000000000000000000000
0.30.270.61-0.020.510.030.371.30.070.850.01-0.492.1-1.713.512.51-0.594.1-0.32-9.934.92.4120.12-4.15-5.54-1.736.040.541.322.61-0.94-0.948.76-12.76-1.1-3.5235.95
-126-7-155-183-474-665-1,117-510-65178-207-1,651-1,906183-2,892-4,336-11,965-5,647-3,346-6,247-9,535-426-91-934-8,847-7,660-14,540-3,998-4,897-3,981-4,138-10,939-8,4714250-2,0000
-0.07-0.060.14-0.74-0.46-1.33-1.54-0.11-0.86-0.18-1.49-3.64-1.63-3.73-2.1-5-16.91-6.63-9.22-23.1-12.61-6.5614.48-11.17-20.61-16-14.98-10.19-10.41-9.23-13.35-20.44-8.49-9.65-9.82-14.8326.07
0.050.010.040.070.180.070.050.020.15-0.06000000000000000.02-0.080.11-0.120.11-0.54-0.61-0.59-0.7411.120.02-0.34-0.63
-297-330-364-601-674-762-844-921-1,010-1,145-1,294-1,501-1,820-2,197-2,715-3,168-4,353-5,082-5,555-6,919-7,975-8,541-5,548-6,088-6,234-6,534-6,580-6,609-6,940-7,317-7,659-7,978-8,043-8,440-8,729-8,983-9,247
0.13-0.140.160.10.670.13-0.810.51-0.980.840.110.79-0.05-1.26-0.060.84-0.360.290.44-0.421.58-1.28-0.14-0.241.456.9-7.91.160.3-1.04-1.24-0.210.130.480.16-1.522.45
1,0355292006016634387491,0531,5381,9061,8843,0002,7273,8536,8427,8978,31013,41212,19615,39111,47316,53715,3829,94118,35815,32716,21915,50113,19114,19414,58513,6319,99311,61229,86926,0314,793
0000000000000000000000000000000000000

Pfizer stock margins

The Pfizer margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pfizer. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pfizer.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pfizer's sales revenue. A higher gross margin percentage indicates that the Pfizer retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pfizer's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pfizer's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pfizer's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pfizer. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pfizer's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pfizer Margin History

Pfizer Gross marginPfizer Profit marginPfizer EBIT marginPfizer Profit margin
2029e69.59 %0 %25.52 %
2028e69.59 %32.33 %25.91 %
2027e69.59 %33.94 %26.73 %
2026e69.59 %32.73 %25.97 %
2025e69.59 %31.38 %24.64 %
2024e69.59 %28.84 %21.96 %
202369.59 %22.39 %3.62 %
202266.02 %40.03 %31.27 %
202162.25 %33.87 %27.04 %
202079.54 %27.96 %22.95 %
201980.46 %22.87 %39.52 %
201878.27 %21.4 %27.32 %
201779.37 %29.66 %40.55 %
201677.43 %28.51 %13.66 %
201580.4 %27.91 %14.25 %
201480.8 %29.55 %18.41 %
201381.64 %32.99 %42.65 %
201282.03 %31.68 %26.65 %
201180.83 %30.74 %16.4 %
201078.1 %26.92 %12.67 %
200982.99 %32.25 %17.52 %
200884.75 %34.2 %16.77 %
200776.79 %22.43 %16.81 %
200684.21 %31.04 %39.97 %
200584.74 %30.64 %17.04 %
200486.95 %33.48 %23.18 %

Pfizer Stock Sales Revenue, EBIT, Earnings per Share

The Pfizer earnings per share therefore indicates how much revenue Pfizer has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Pfizer earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pfizer's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pfizer’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pfizer's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pfizer Revenue, EBIT and net profit per share

DatePfizer Sales per SharePfizer EBIT per sharePfizer Earnings per Share
2029e10.96 undefined0 undefined2.8 undefined
2028e11.11 undefined0 undefined2.88 undefined
2027e11.47 undefined0 undefined3.07 undefined
2026e11.28 undefined0 undefined2.93 undefined
2025e11.19 undefined0 undefined2.76 undefined
2024e10.8 undefined0 undefined2.37 undefined
202310.25 undefined2.29 undefined0.37 undefined
202217.5 undefined7 undefined5.47 undefined
202114.24 undefined4.82 undefined3.85 undefined
20207.44 undefined2.08 undefined1.71 undefined
20197.25 undefined1.66 undefined2.87 undefined
20186.83 undefined1.46 undefined1.87 undefined
20178.67 undefined2.57 undefined3.52 undefined
20168.58 undefined2.45 undefined1.17 undefined
20157.81 undefined2.18 undefined1.11 undefined
20147.72 undefined2.28 undefined1.42 undefined
20137.48 undefined2.47 undefined3.19 undefined
20127.28 undefined2.31 undefined1.94 undefined
20117.76 undefined2.38 undefined1.27 undefined
20108.07 undefined2.17 undefined1.02 undefined
20096.99 undefined2.26 undefined1.23 undefined
20087.15 undefined2.45 undefined1.2 undefined
20076.98 undefined1.57 undefined1.17 undefined
20066.65 undefined2.06 undefined2.66 undefined
20056.4 undefined1.96 undefined1.09 undefined
20046.43 undefined2.15 undefined1.49 undefined

Pfizer business model

Pfizer Inc, one of the world's largest and most well-known pharmaceutical companies, has made significant advancements in the medical industry throughout its approximately 170-year history. The company is headquartered in New York City and has offices in over 150 countries. Pfizer was founded in 1849 by two cousins, Charles Pfizer and Charles Erhart, who opened their first factory in Brooklyn to produce pure crystalline chinasalt. They later expanded their business and began synthesizing chemical compounds, leading them to enter the pharmaceutical industry. In the following years, Pfizer made some significant discoveries, including the synthesis of antibiotics such as penicillin and terramycin. In the 1990s, the company expanded its portfolio and became a leading provider of prescription drugs, immunological medications, and animal health products. Today, the company focuses on three core areas: innovative health products, patented medications, and generic products. Pfizer invests millions of dollars in research and development of new and innovative treatment options, including cancer drugs, therapies for neurological disorders, cardiovascular diseases, and immunology products. Another important aspect of Pfizer's business model is its partnerships with other companies and organizations. The company works closely with universities, research institutions, governments, and other companies to form partnerships that allow for collaborative development of new products. Some of Pfizer's most well-known products include Viagra, Lipitor, Celebrex, Zoloft, and Lyrica. Viagra is used to treat erectile dysfunction in men. Lipitor is a cholesterol-lowering medication that reduces the risk of cardiovascular diseases. Celebrex is an anti-inflammatory medication used to treat pain and inflammation. Zoloft is an antidepressant used to treat various mental disorders. Lyrica is a prescription medication used to treat pain and seizures. In recent years, Pfizer has also taken a leading role in the development of vaccines against COVID-19, collaborating with the German company BioNTech to develop a promising vaccine candidate. The vaccine provides protection against the virus, particularly against severe illness. Over the years, the company has faced concerns regarding the use of medications, such as the scandal surrounding the pain reliever Vioxx, which was withdrawn in 2004 after being associated with an increased risk of cardiovascular diseases. Pfizer has since strengthened its research and development standards and partnerships to ensure the safety and efficacy of its products. In summary, Pfizer is a global player in the pharmaceutical industry. The company heavily invests in research and development of new products to provide innovative treatment options, secures patents, and simultaneously keeps its portfolio up-to-date with generic products to remain competitive in the industry. The company will continue to contribute to improving healthcare worldwide by developing lifesaving medications and vaccines that enable people to lead better lives. Pfizer is one of the most popular companies on Eulerpool.com.

Pfizer SWOT Analysis

Strengths

Pfizer Inc. possesses several strengths that contribute to its success in the pharmaceutical industry. One of its key strengths is its extensive portfolio of innovative drugs and treatments. The company invests heavily in research and development, allowing it to continuously develop and introduce new products to the market. Pfizer's strong brand reputation and global presence also contribute to its competitive advantage.

Another major strength is Pfizer's robust financial position. The company has a solid revenue stream, driven by the high demand for its products, and maintains a strong profitability margin. This financial stability enables Pfizer to invest in strategic acquisitions and partnerships, further strengthening its position in the industry.

Weaknesses

Despite its strengths, Pfizer Inc. also faces certain weaknesses that need to be addressed. One weakness is its heavy reliance on a few key products for a significant portion of its revenue. This exposes the company to risks associated with patent expirations and competition from generic drug manufacturers. Pfizer needs to focus on diversifying its product portfolio to reduce this dependency.

Another weakness is the potential negative impact of regulatory changes and legal issues on Pfizer's operations. The pharmaceutical industry is subject to strict regulations, and any change or legal challenge can disrupt Pfizer's business activities and profitability. Close monitoring of regulatory developments and proactive compliance strategies are essential to mitigate these risks.

Opportunities

Pfizer Inc. has several opportunities to capitalize on in the constantly evolving pharmaceutical market. One significant opportunity lies in the growing demand for personalized medicine and targeted therapies. Pfizer can leverage its expertise and research capabilities to develop innovative treatments that cater to specific patient populations, creating a competitive edge in the market.

Furthermore, the increasing focus on healthcare and medical advancements presents an opportunity for Pfizer to expand into emerging markets with high growth potential. By targeting underserved regions, the company can tap into new customer segments and drive revenue growth. Strategic collaborations with local healthcare providers and governments can further enhance Pfizer's market penetration in these regions.

Threats

Like any other company in the pharmaceutical industry, Pfizer Inc. faces several threats that could impact its business. One major threat is the intense competition within the market. The industry is highly competitive, with numerous pharmaceutical companies striving to develop breakthrough drugs and gain market share. Pfizer needs to continuously innovate and stay ahead to maintain its competitive position.

Additionally, the potential risk of counterfeit drugs poses a threat to Pfizer's reputation and revenue. Counterfeit drugs can harm patients and erode trust in the company's products. Pfizer should strengthen its supply chain security and invest in advanced technologies to detect and combat counterfeit drugs effectively.

Moreover, changes in healthcare policies and pricing regulations can significantly impact Pfizer's profitability. Government policies aimed at cost containment or price controls can restrict the company's ability to set prices for its products, thereby affecting its financial performance. Continuous monitoring of these policies and proactive engagement with policymakers is crucial to minimize potential risks.

Pfizer historical P/E ratio, EBIT, and P/S ratio.

Pfizer shares outstanding

The number of shares was Pfizer in 2023 — This indicates how many shares 5.709 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Pfizer earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pfizer's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pfizer’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pfizer's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pfizer Stock splits

In Pfizer's history, there have been no stock splits.

Pfizer dividend history and estimates

In 2023, Pfizer paid a dividend amounting to 2.05 USD. Dividend means that Pfizer distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Pfizer provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Pfizer’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Pfizer's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Pfizer Dividend History

DatePfizer Dividend
2029e2.43 undefined
2028e2.43 undefined
2027e2.44 undefined
2026e2.42 undefined
2025e2.45 undefined
2024e2.45 undefined
20232.05 undefined
20221.6 undefined
20211.56 undefined
20201.52 undefined
20191.44 undefined
20181.36 undefined
20171.58 undefined
20161.5 undefined
20151.12 undefined
20141.04 undefined
20130.96 undefined
20120.88 undefined
20110.8 undefined
20100.72 undefined
20090.8 undefined
20081.28 undefined
20071.16 undefined
20060.96 undefined
20050.76 undefined
20040.68 undefined

Pfizer dividend payout ratio

In 2023, Pfizer had a payout ratio of 53.06%. The payout ratio indicates the percentage of the company's profits that Pfizer distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Pfizer represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Pfizer could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Pfizer's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Pfizer Payout Ratio History

DatePfizer Payout ratio
2029e43.4 %
2028e42.82 %
2027e42.35 %
2026e45.03 %
2025e41.08 %
2024e40.94 %
202353.06 %
202229.24 %
202140.52 %
202089.41 %
201950.35 %
201873.12 %
201745.01 %
2016128.21 %
2015100.9 %
201473.76 %
201330.09 %
201245.36 %
201162.99 %
201069.9 %
200966.12 %
2008107.56 %
200798.31 %
200636.23 %
200569.72 %
200445.64 %
Unfortunately, there are currently no price targets and forecasts available for Pfizer.

Pfizer latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20240.53 0.82  (55.04 %)2024 Q1
12/31/2023-0.22 0.1  (145.39 %)2023 Q4
9/30/2023-0.34 -0.17  (49.9 %)2023 Q3
6/30/20230.57 0.67  (16.85 %)2023 Q2
3/31/20230.99 1.23  (24.56 %)2023 Q1
12/31/20221.06 1.14  (7.71 %)2022 Q4
9/30/20221.4 1.78  (27.02 %)2022 Q3
6/30/20221.8 2.04  (13.38 %)2022 Q2
3/31/20221.49 1.67  (12.21 %)2022 Q1
12/31/20210.87 1.08  (23.51 %)2021 Q4
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Pfizer stock

Eulerpool World ESG Rating (EESG©)

72/ 100

🌱 Environment

75

👫 Social

87

🏛️ Governance

53

Environment

Scope 1 - Direct Emissions
662,438
Scope 2 - Indirect emissions from purchased energy
502,139
Scope 3 - Indirect emissions within the value chain
4,754,878
Total CO₂ emissions
1,164,577
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees47.7
Percentage of women in management
Percentage of Asian employees8
Share of Asian management19.9
Percentage of Hispanic/Latino employees7
Hispano/Latino Management share6.1
Percentage of Black employees20
Black Management Share5.5
Percentage of white employees62
White Management Share66.7
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pfizer list of shareholders

%
Name
Stocks
Change
Date
8.90 % The Vanguard Group, Inc.504,052,453-256,66112/31/2023
5.07 % State Street Global Advisors (US)287,482,0064,786,06812/31/2023
4.85 % BlackRock Institutional Trust Company, N.A.274,898,256-12,951,72712/31/2023
4.22 % Wellington Management Company, LLP239,209,76811,099,02412/31/2023
3.06 % Capital World Investors173,394,272-8,798,01012/31/2023
1.93 % Geode Capital Management, L.L.C.109,534,2172,448,39312/31/2023
1.84 % Charles Schwab Investment Management, Inc.104,246,4328,473,68612/31/2023
1.31 % Norges Bank Investment Management (NBIM)73,981,48012,496,85812/31/2023
1.17 % MFS Investment Management66,508,2617,506,07112/31/2023
0.96 % State Farm Insurance Companies54,508,560012/31/2023
1
2
3
4
5
...
10

Pfizer Executives and Management Board

Dr. Albert Bourla61
Pfizer Chairman of the Board, Chief Executive Officer (since 2014)
Compensation 33.02 M
Mr. David Denton57
Pfizer Executive Vice President, Chief Financial Officer
Compensation 24.44 M
Dr. Mikael Dolsten66
Pfizer Chief Scientific Officer, President - Worldwide Research, Development and Medical
Compensation 12.22 M
Mr. Douglas Lankler57
Pfizer Executive Vice President, General Counsel
Compensation 7.13 M
Dr. Scott Gottlieb50
Pfizer Independent Director
Compensation 553,645
1
2
3
4
...
5

Pfizer Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer-0,56----
SupplierCustomer--0,31-0,550,280,260,50
SupplierCustomer0,61-0,09-0,290,39-0,610,17
SupplierCustomer0,580,820,40-0,470,14-0,56
SupplierCustomer0,560,810,79-0,280,600,81
SupplierCustomer0,560,88-0,070,48-0,71-0,65
Clovis Oncology, Inc. Stock
Clovis Oncology, Inc.
SupplierCustomer0,550,950,700,57-0,74-0,82
SupplierCustomer0,540,910,240,38-0,140,57
SupplierCustomer0,540,880,410,50-0,380,08
SupplierCustomer0,540,590,330,250,570,63
1
2
3
4
5
...
25

Most common questions regarding Pfizer

What values and corporate philosophy does Pfizer represent?

Pfizer Inc, a renowned pharmaceutical company, represents values of integrity, excellence, and patient-centricity. With a strong corporate philosophy, Pfizer aims to improve the health and well-being of individuals worldwide through innovative medicines and therapies. Committed to scientific advancement, Pfizer provides quality healthcare solutions while upholding ethical practices. Through extensive research and development, they strive to discover and deliver life-saving and life-enhancing treatments. As a global leader in the healthcare industry, Pfizer's dedication to patient care, scientific ingenuity, and ethical principles are fundamental to their corporate philosophy and drive their mission to revolutionize healthcare for a better tomorrow.

In which countries and regions is Pfizer primarily present?

Pfizer Inc is primarily present in various countries and regions across the globe. The company has a widespread presence with operations in multiple key markets. Pfizer's global presence includes major countries such as the United States, United Kingdom, Germany, Japan, China, India, Brazil, and many more. With a diverse international footprint, Pfizer Inc continues to serve patients and healthcare professionals worldwide by delivering innovative healthcare solutions and medications.

What significant milestones has the company Pfizer achieved?

Pfizer Inc has achieved significant milestones throughout its history. Founded in 1849, the company has become one of the world's leading pharmaceutical corporations. Notably, Pfizer developed and marketed groundbreaking drugs that have revolutionized medical treatments. In 1998, the company gained immense recognition with the introduction of Viagra, a medication for erectile dysfunction. Pfizer's research and innovation also led to the development of Lipitor, a cholesterol-lowering drug that became the best-selling prescription medicine worldwide. Furthermore, Pfizer remains dedicated to advancing healthcare by continuously expanding its product portfolio and pursuing collaborations to address unmet medical needs. With its rich history and commitment to innovation, Pfizer Inc continues to make significant contributions to the healthcare industry.

What is the history and background of the company Pfizer?

Pfizer Inc. is a renowned pharmaceutical giant with a rich history and influential background. Established in 1849, Pfizer has evolved into one of the largest global pharmaceutical companies. Headquartered in New York City, Pfizer has played a pivotal role in the healthcare industry's advancement. The company is committed to developing innovative medicines and vaccines that improve and save lives worldwide. With its vast expertise, extensive research and development efforts, and strategic collaborations, Pfizer has introduced groundbreaking treatments for various diseases. As a leader in the pharmaceutical sector, Pfizer continues to prioritize delivering transformative healthcare solutions to address the evolving needs of patients and healthcare professionals.

Who are the main competitors of Pfizer in the market?

The main competitors of Pfizer Inc in the market include pharmaceutical companies such as Johnson & Johnson, Novartis AG, Merck & Co., Inc., and GlaxoSmithKline plc.

In which industries is Pfizer primarily active?

Pfizer Inc is primarily active in the pharmaceutical industry.

What is the business model of Pfizer?

Pfizer Inc's business model is focused on pharmaceutical research, development, manufacturing, and sales. The company operates in various therapeutic areas, including but not limited to oncology, cardiovascular, immunology, and neurology. Pfizer's mission is to discover and develop innovative medicines that enhance the health and well-being of people worldwide. With a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products, Pfizer strives to improve patient outcomes and provide effective healthcare solutions. Through strategic partnerships and collaborations, Pfizer continues to invest in research and development to address unmet medical needs and drive sustainable growth in the pharmaceutical industry.

What is the P/E ratio of Pfizer 2024?

The Pfizer P/E ratio is 12.53.

What is the P/S ratio of Pfizer 2024?

The Pfizer P/S ratio is 2.75.

What is the AlleAktien quality score of Pfizer?

The AlleAktien quality score for Pfizer is 3/10.

What is the revenue of Pfizer 2024?

The expected Pfizer revenue is 61.19 B USD.

How high is the profit of Pfizer 2024?

The expected Pfizer profit is 13.44 B USD.

What is the business model of Pfizer

Pfizer Inc is a multinational pharmaceutical company headquartered in New York City. The company operates in the research, development, production, and distribution of drugs. Pfizer is one of the largest pharmaceutical companies in the world. In this article, we will describe the business model of Pfizer Inc. Divisions Pfizer has divided its business operations into three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. Biopharmaceuticals The Biopharmaceuticals division focuses on the research and development of drugs. The goal is to develop new drugs and therapies that meet the needs of patients. Research and development are focused on various areas such as oncology, cardiovascular, immunological, and neuroscience disorders. Pfizer has a strong pipeline with numerous drugs in late-stage clinical development. An example is the drug Tofacitinib, which is used to treat rheumatoid arthritis. In 2020, Pfizer generated revenue of $51.8 billion in this division. Beyond the Baby Cure The Beyond the Baby Cure division refers to products that are not drug-based. This includes products like vitamin-rich dietary supplements, pain relievers, condoms, and personal care products. Pfizer acquired Wyeth in 2006, a company active in this segment. This allowed Pfizer to expand its product portfolio. In 2020, Pfizer generated revenue of $2.5 billion in this segment. Contract Manufacturing Pfizer's Contract Manufacturing division refers to the production of drugs for other companies. The company offers services for the entire value chain, from drug manufacturing to logistics. In 2020, Pfizer generated revenue of $2.2 billion in this division. Products Pfizer offers a wide range of products covering various areas. Here are some of Pfizer's key products: - Viagra, a medication for the treatment of erectile dysfunction - Lyrica, a medication for the treatment of neuropathic pain - Prevnar, a vaccine for the prevention of pneumococcal infections - Xeljanz, a medication for the treatment of rheumatoid arthritis - Lipitor, a medication for lowering cholesterol levels Conclusion Pfizer is a leading pharmaceutical company with a broad portfolio of products and services. The company specializes in three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. With a strong commitment to research and development and an impressive pipeline, Pfizer has a strong position in the industry.

What is the Pfizer dividend?

Pfizer pays a dividend of 1.6 USD distributed over 4 payouts per year.

How often does Pfizer pay dividends?

Pfizer pays out a dividend 4 times a year.

What is the Pfizer ISIN?

The ISIN of Pfizer is US7170811035.

What is the Pfizer WKN?

The WKN of Pfizer is 852009.

What is the Pfizer ticker?

The ticker of Pfizer is PFE.

How much dividend does Pfizer pay?

Over the past 12 months, Pfizer paid a dividend of 2.05 USD . This corresponds to a dividend yield of about 6.95 %. For the coming 12 months, Pfizer is expected to pay a dividend of 2.45 USD.

What is the dividend yield of Pfizer?

The current dividend yield of Pfizer is 6.95 %.

When does Pfizer pay dividends?

Pfizer pays a quarterly dividend. This is distributed in the months of December, February, June, August.

How secure is the dividend of Pfizer?

Pfizer paid dividends every year for the past 26 years.

What is the dividend of Pfizer?

For the upcoming 12 months, dividends amounting to 2.45 USD are expected. This corresponds to a dividend yield of 8.29 %.

In which sector is Pfizer located?

Pfizer is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pfizer kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pfizer from 9/3/2024 amounting to 0.42 USD, you needed to have the stock in your portfolio before the ex-date on 7/26/2024.

When did Pfizer pay the last dividend?

The last dividend was paid out on 9/3/2024.

What was the dividend of Pfizer in the year 2023?

In the year 2023, Pfizer distributed 1.6 USD as dividends.

In which currency does Pfizer pay out the dividend?

The dividends of Pfizer are distributed in USD.

All fundamentals about Pfizer

Our stock analysis for Pfizer Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pfizer Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.